Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Uterine Cancer.
The Uterine Cancer Market Size was valued at USD 15.43 Billion in 2023 and is projected to grow from USD 16.89 Billion in 2024 to USD 24.08 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.21% during the forecast period.
Also known as endometrial cancer, uterine cancer is the abnormal development of endometrium cells in the uterus that often causes vaginal bleeding. Uterine cancer is the sixth most frequent cancer in women worldwide.
The uterine cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation, and curettage (D&C), and laparoscopy. The therapeutic market for uterine cancer includes hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care.
For additional information on Uterine (Endometrial) cancer, please review the video by Medical Centric.